American Osteopathic Association

Advancing the distinctive philosophy and practice of osteopathic medicine

CO*RE REMS Programs

 

 2017 CO*RE REMS Programs

 

In partnership with CO*RE, AOA offers grants for hosting "Opioid Prescribing: Safe Practice, Changing Lives" programs. AOA affiliates can apply for a block grant to present live Category 1-A CME developed by the Collaborative for REMS Education (CO*RE). For more information, email Stephanie Townsell, Director of Public Health, at stownsell@osteopathic.org.

Past Courses

 

 CO*RE REMS Program Information

 

​On July 9, 2012, the U.S. Food and Drug Administration (FDA) announced a risk evaluation and mitigation strategy (REMS) for extended-release (ER) and long-acting (LA) opioid products. The goal of the REMS is to reduce serious adverse outcomes resulting from inappropriate prescribing, misuse, and abuse of ER/LA opioid analgesics while maintaining patient access to these pain medications. Adverse outcomes of concern include addiction, unintentional overdose and death.

To ensure that the benefits of ER/LA opioid analgesics outweigh the risks, the FDA has required ER/LA opioid analgesics manufacturers, known as the REMS Program Companies (RPC), to provide education for prescribers of these medications. RPC-supported REMS education will be provided through accredited continuing education activities, supported by independent educational grants from these ER/LA opioid analgesic companies. AOA is a member of the Collaborative for REMS Education (CO*RE), a partnership funded by the RPC to provide courses that address prescription drug abuse in the U.S.

 

 Other REMS Opportunities

 

​For information regarding ER/LA REMS or RPC grants available for funding ER/LA REMS activities, visit the ER/LA Opioid Analgesic REMS website.

Accredited CE providers developing CE activities around these medications may wish to download the FDA Blueprint for Prescriber Education of ER/LA Opioid Analgesics.

 

 Share This